4.4 Article

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

S. E. Dorman et al.

Summary: The study found that a 4-month rifapentine-based regimen containing moxifloxacin was noninferior to the standard 6-month regimen in the treatment of tuberculosis, supporting the noninferiority hypothesis. This regimen was effective in both the microbiologically eligible population and the assessable population.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Critical Care Medicine

Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Payam Nahid et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)

Article Critical Care Medicine

Daily Rifapentine for Treatment of Pulmonary Tuberculosis A Randomized, Dose-Ranging Trial

Susan E. Dorman et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)

Article Medicine, General & Internal

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

Ian M. Rosenthal et al.

PLOS MEDICINE (2007)

Article Critical Care Medicine

Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis

IM Rosenthal et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)